Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

10-21	Allergan Aesthetics presents its latest scientific advances
09-29	Abbvie Through Allergan Aesthetics Receives Health Canada Authorization for Boey for Frown Lines	CI

Market Cap	63.66B 56.87B 52.24B 47.45B 89.1B 6,030B 91.34B 624B 251B 3,183B 239B 234B 10,088B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 72.33B 66.44B 60.34B 113B 7,670B 116B 793B 319B 4,048B 304B 297B 12,830B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

10-21	Allergan Aesthetics presents its latest scientific advances
09-29	Abbvie Through Allergan Aesthetics Receives Health Canada Authorization for Boey for Frown Lines	CI
09-17	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
09-15	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI
09-02	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
04-08	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
04-01	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
03-30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
03-19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
03-04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
11-13	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25/09/25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
19/08/25	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI

01/04/24	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
20/04/22	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
06/04/22	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22/03/22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
10/12/21	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

10-21	Allergan Aesthetics présente ses dernières avancées scientifiques
20/04/21	Planète Bourse : La revue de presse du mardi 20 avril 2021
07/05/20	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
07/05/20	La Chine repart, mais Washington veille
06/05/20	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...

Actavis PLC Stock NYSE

Stocks

US00507K1034

Pharmaceuticals

Valuation: Actavis PLC

Latest news: Actavis PLC

Press Releases: Actavis PLC

News in other languages: Actavis PLC

Managers and Directors: Actavis PLC

Other Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
Scott Reents BRD	Director/Board Member	-	08/05/2020
Ryan Quigley BRD	Director/Board Member	-	08/05/2020
Andres Rodrigo BRD	Director/Board Member	-	08/05/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+0.47%	+10.95%	+58.64%	+150.49%	1,257B
JOHNSON & JOHNSON	-1.10%	-0.24%	+43.93%	+77.13%	651B
ABBVIE INC.	-0.09%	+0.82%	+36.23%	+104.18%	510B
ROCHE HOLDING AG	-1.56%	-2.01%	+50.67%	+64.81%	388B
MERCK & CO., INC.	-2.62%	+2.31%	+75.90%	+40.36%	366B
NOVARTIS AG	-0.02%	+2.11%	+32.16%	+57.79%	303B
ASTRAZENECA PLC	-0.72%	+7.32%	+11.29%	+33.98%	288B
AMGEN INC.	-0.46%	+3.49%	+56.46%	+71.79%	252B
GILEAD SCIENCES, INC.	-1.00%	+6.33%	+38.59%	+107.32%	211B
Average	-0.74%	+4.59%	+44.88%	+78.65%	469.63B
Weighted average by Cap.	-0.52%	+5.30%	+48.17%	+94.76%

	2018	2019
Net sales	15.79B 14.1B 12.96B 11.77B 22.1B 1,496B 22.65B 155B 62.21B 789B 59.26B 57.99B 2,502B	16.09B 14.37B 13.2B 11.99B 22.52B 1,524B 23.08B 158B 63.4B 804B 60.39B 59.1B 2,550B
Net income	-5.1B -4.55B -4.18B -3.8B -7.13B -483B -7.31B -49.92B -20.08B -255B -19.13B -18.72B -808B	-5.27B -4.71B -4.33B -3.93B -7.38B -499B -7.56B -51.63B -20.77B -264B -19.78B -19.36B -835B
Net Debt	21.89B 19.56B 17.96B 16.32B 30.64B 2,074B 31.41B 214B 86.26B 1,094B 82.17B 80.41B 3,469B	17.3B 15.46B 14.2B 12.9B 24.22B 1,639B 24.83B 170B 68.19B 865B 64.95B 63.56B 2,742B

End-of-day quote NYSE
- ^USD	-